Augur Signals: News Feed

Report Archive – November 2023

Augur Signals: News Feed
Asset Management , Financial Services , Alert

Insider Trading Alert: Analyzing the Recent Activity in Kayne Anderson Energy Infrastructure Fund

  • Acquired: Non-Derivative
Insider Trading Alert: Analyzing the Recent Activity in Kayne Anderson Energy Infrastructure Fund
An insider trading alert was triggered for Kayne Anderson Energy Infrastructure Fund, Inc. (KYN) on November 28, 2023, due to a significant purchase by insider Hart Terry A. He acquired 15,354 shares valued at approximately $127,898.82, increasing his total holdings to 51,958 shares. The financial services sector faces economic uncertainty, yet KYN shows resilience with a low P/E ratio of 4.52. The recent purchase reflects confidence in the company's future, predicting a potential stock price increase to $8.70 to $8.90 in the short term.
Leisure , Consumer Cyclical , Alert

Insider Trading Alert: Key Insights and Market Predictions

  • Acquired: Non-Derivative
Insider Trading Alert: Key Insights and Market Predictions
On November 21, 2023, Gary L. Mcarthur, a director at Vista Outdoor Inc., purchased 1,735 shares for approximately $44,728.30, increasing his holdings to 94,560 shares. The stock, trading at $25.78 on that day, shows potential upside with a P/E ratio of 9.63. Gary L. Mcarthur's transactions historically yield a 10.23% ROI, indicating confidence in the company's prospects. Projections suggest a stock price rise to $27.00 in the short term, reflecting positive market sentiment.
Medical Devices , Healthcare , Alert

Insider Trading Alert: A Close Look at Recent Purchases by Encrantz Staffan

  • Acquired: Non-Derivative
Insider Trading Alert: A Close Look at Recent Purchases by Encrantz Staffan
On , significant insider trading activity was reported for Sight Sciences, Inc. (SGHT) by insider Encrantz Staffan, a director and ten percent owner. He acquired 120,319 shares, increasing his holdings to 346,295 shares, with a market value change of $205,745.49. The company's current valuation, with a P/E ratio of -4.38, P/B ratio of 2.12, and P/S ratio of 2.53, suggests potential growth. Insider confidence indicates a positive price movement, with targets of $2.75 to $3.00 in the short term.
Agricultural Inputs , Basic Materials , Alert

Insider Trading Alert: American Vanguard Corporation

  • Acquired: Non-Derivative
Insider Trading Alert: American Vanguard Corporation
On November 17, 2023, Trogele Ulrich, a director at American Vanguard Corporation (AVD), purchased 10,786 shares of common stock worth approximately $98,907.62. This increased his total holdings to 179,173 shares. The transaction occurred on the NYQ exchange when the stock was priced at $9.17, below its 16-week average of $12.25. Despite a high Price-to-Earnings ratio of 13.49, the company's Price-to-Book and Price-to-Sales ratios indicate undervaluation. This insider activity suggests potential stock appreciation, with predictions of short-term price targets between $9.50 and $10.50.
Medical Devices , Healthcare , Alert

Insider Trading Alert: A Strategic Move in Sight Sciences, Inc.

  • Acquired: Non-Derivative
Insider Trading Alert: A Strategic Move in Sight Sciences, Inc.
On November 16, 2023, Encrantz Staffan, a director of Sight Sciences, Inc. (SGHT), purchased 339 shares valued at approximately $695. This transaction increased his holdings to 30,835 shares. The healthcare sector, particularly medical devices, shows growth potential, with Sight Sciences, Inc. being modestly undervalued. Recent insider activity and market conditions suggest a bullish sentiment, with the stock's price moving from $2.05 to $2.50. Projections estimate a near-term price increase to $2.60 to $3.00, contingent on favorable market conditions.
Biotechnology , Healthcare , Alert

Insider Trading Alert: Strategic Acquisition by Iterum Therapeutics' Director

  • Acquired: Non-Derivative
Insider Trading Alert: Strategic Acquisition by Iterum Therapeutics' Director
Fishman Corey N., a director at Iterum Therapeutics plc, purchased 10,000 shares at $1.38 each, totaling $13,800, on November 20, 2023. This acquisition increased his holdings to 54,449 shares. His insider activity shows a positive ROI of 10.59%. The biotech sector's volatility and increased trading volume indicate potential growth. Despite a negative P/E ratio of -3.27, the purchase may signal confidence in future profitability. Short-term stock price predictions range from $1.45 to $1.70.
Medical Devices , Healthcare , Alert

Insider Trading Alert: Insight into Beyond Air, Inc.'s Recent Activity

  • Acquired: Non-Derivative
Insider Trading Alert: Insight into Beyond Air, Inc.'s Recent Activity
Michael A. Gaul, an officer at Beyond Air, Inc., purchased 10,000 shares of the company's stock for approximately $15,750 on November 16, 2023. This transaction occurred as stock prices declined, closing at $1.575. Gaul, an insider since August 22, 2022, has consistently engaged with the stock, with a positive 4-week ROI of 12.8%. Despite a negative P/E ratio, the P/B ratio suggests undervaluation, while the high P/S ratio indicates potential overvaluation. Short-term price targets are $1.65 to $1.70.
Medical Instruments & Supplies , Healthcare , Alert

Insider Trading Alert: Pulse Biosciences, Inc.

  • Acquired: Non-Derivative
Insider Trading Alert: Pulse Biosciences, Inc.

On November 16, 2023, Kevin Patrick Danahy, an officer at Pulse Biosciences, Inc., bought 5,381 shares valued at about $69.6k. This increased his total holdings to 35,875 shares. The stock's recent closing price was $6.24, with a high RSI of 76.67, indicating overbought conditions. Despite a negative P/E ratio of -22.63, the high P/B ratio of 15.84 suggests confidence in asset utilization. The stock may rise to $6.40 - $6.50 in the short term, stabilizing around $6.20 - $6.30 later.

Biotechnology , Healthcare , Alert

Insider Trading Alert: Analyzing the Implications for Agenus Inc.

  • Acquired: Non-Derivative
Insider Trading Alert: Analyzing the Implications for Agenus Inc.
On November 15, 2023, Ulf Wiinberg of Agenus Inc. purchased 1,246 shares of Common Stock, bringing his total to 124,063 shares. The stock, trading at $14.80, shows potential for a rebound due to its undervaluation, with a P/E ratio of -0.35 and a P/S ratio of 0.52. Analysts predict a short-term price increase to around $17.00, driven by strategic insider actions and favorable market conditions in the Biotechnology sector.
Medical Devices , Healthcare , Alert

Sight Sciences, Inc. Insider Trading Alert: A Strategic Move by Encrantz Staffan

  • Acquired: Non-Derivative
Sight Sciences, Inc. Insider Trading Alert: A Strategic Move by Encrantz Staffan
On November 14, 2023, Encrantz Staffan, a director and ten percent owner of Sight Sciences, Inc., purchased 3,462 shares of Common Stock valued at approximately $7,131.72. This transaction adds to his total holdings of 30,496 shares. The stock, with a P/E ratio of -4.38, suggests potential undervaluation. Market participants anticipate a price increase to $2.10 to $2.15 in the short term. The insider's confidence and strategic investment decisions are noteworthy for potential growth.

Back

Pages total: 3

Calendar